XENOTHERA’s Post

We are excited to share that Dr. Justin Call and the team at START Mountain Region have dosed the first two patients in a Genmab clinical trial! This milestone represents a critical step forward in advancing innovative cancer treatments for patients with advanced solid tumors.   The study is designed to evaluate safety, tolerability, and anti-tumor activity, aiming to refine treatment options and bring new hope to patients facing advanced cancers.   We are honored to collaborate with Genmab on this important research and remain committed to pushing the boundaries of oncology to improve outcomes for patients worldwide.   To learn more about this study, please visit: https://lnkd.in/ezQaiaWS #oncology #cancerresearch #clinicaltrials Marie (Asay) Park MS, RN, OCN, William McKean

🎥 Exciting updates on OMX-0407 from #ESMO24! 🎥   We spoke to Dr. Valentina Boni, Principal Investigator at a Madrid clinical trial site for the first-in-human trial with OMX-0407. She shared her experiences of the dose escalation study, including the complete response of a patient with angiosarcoma. Dr. Boni describes the patient's journey after two lines of standard chemotherapy before the trial and how OMX-0407 led to the complete disappearance of tumor lesions.   Expansion cohorts are currently underway in Spain and Belgium to further evaluate OMX-0407 in kidney cancer and angiosarcoma.   Watch the video to learn more about OMX-0407 and stay tuned for more updates on our promising drug candidate.   ESMO - European Society for Medical Oncology Tiantom (Dom) J.   #ImmunoOncology #oncology #ClinicalResearch #ClinicalTrials

Incredible scientists, physicians and experts in clinical research. Great teams collaborating and enhancing the knowledge in oncology. #ESMO2024 #Oncology #ClinicalTrials #CancerResearch #Innovation #MedicalAdvances #Collaboration #ClinicalTrials #ClinicalResearch

Ranger® Technology - Ranger® for Oncology Suitable for oncology early detection and disease progression studies Circulating tumour DNA (ctDNA) is extremely low due to dilution by abundant normal circulating cell-free DNA (ccfDNA). The application of ctDNA diagnostics for early disease detection requires reliable identification of VAFs as low as <1% and remains a principal obstacle to widespread application of cfDNA in clinical oncology Employing Ranger® Technology’s automated size selection can: ✔️Enrich fragments of tumour origin ✔️Reduce sample complexity ✔️Improve sensitivity in cancer ctDNA-based applications ✔️Including detection of very low variant allele frequencies Read more here:https://hubs.la/Q02VPMYS0 #RangerTechnology #SizeSelection #ReproductiveHealth #DNA #FetalFraction #ctDNA #ccfDNA #Oncology

🚨 Excited to present our latest research at #ESMO24 on HER2 Expression across Solid Tumors and its Real-World Implications for the Use of fam-trastuzumab deruxtecan-nxki (T-DXd)! 🚨ESMO - European Society for Medical Oncology UAB O'Neal Comprehensive Cancer Center Our study delves deep into the varying expression of HER2 across different solid tumors and provides valuable insights into the practical use of T-DXd 💉 in clinical settings. Here are some key takeaways: ▪️ Diverse Expression Patterns: HER2 shows a wide range of expression levels across different tumor types, underscoring the complexity and variability in tumor biology. ▪️ Real-World Data: The study highlights the significance of real-world evidence in understanding HER2 expression and tailoring treatment strategies accordingly. #Oncology #CancerResearch #PrecisionMedicine #TargetedTherapies #HealthcareInnovation #LungCancer #ClinicalPractice Novellia Daiichi Sankyo US AstraZeneca

👉 👉 👉 The future of medical oncology will focus on understanding cancer biology and intercepting the disease before it appears or recurs. In this new podcast of #TJTalks, prof. Giuseppe Curigliano, chair of the Division of Early Drug Development at the IEO European Institute of Oncology in Milan, and professor at the Università degli Studi di Milano, talks with prof. Pruneri Giancarlo about the future of #precisiononcology and his commitment as President- elect of ESMO - European Society for Medical Oncology 🔗 https://lnkd.in/ddcBtKfr #Oncology #CancerResearch #CancerCare #Medicine #ScientificCommunication #ResearchImpact #Patients #CancerTherapy #EvidencedBasedResearch #Cancer

At this year’s #ENASymp24, Léa Sta, PhD presented our latest research in a poster titled “Data analysis and model evaluation of chemotherapy-induced neutropenia – results from the PARTNER trial.” 🔬 Our team at Physiomics plc has developed a precision dosing tool which aims to reduce toxicity for patients treated with docetaxel. The PARTNER trial provided valuable clinical data from prostate cancer patients treated with docetaxel to help validate this tool and confirm its ability to predict levels and timing of episodes of neutropenia associated with docetaxel use. We’re excited to share this work with you and invite you to explore the full poster. Click below to learn more about our findings 👇 https://lnkd.in/e4a-n3dJ #PKPD #Oncology #ClinicalTrials #Neutropenia #PrecisionDosing

KRAS Inhibitors is EOS Intelligence's focus for June and we will be publishing new content every week. The KRAS oncogene has long been a challenging target in cancer therapy, but recent breakthroughs are transforming the competitive landscape. As the race to develop effective KRAS inhibitors intensifies, understanding this dynamic market is crucial for stakeholders. Here's a closer look at the innovations, challenges, and key players shaping the KRAS competitive landscape. The race to develop effective KRAS inhibitors represents a pivotal moment in cancer treatment. Companies that navigate this competitive landscape successfully will unlock new potentials in oncology, bringing hope to patients and advancing the frontiers of medicine. If you wish to discuss, reach out! #KRASInhibitors #CancerTherapy #OncologyInnovation #PrecisionMedicine #PharmaLeadership

This week, we were excited to attend and present at the #2024AACR Annual Meeting. Our data scientist Jianli Zhou shared some of the innovative work on our drug candidate LP-284, currently in Phase 1 #clinicaltrial for Non-Hodgkin's lymphomas (#NHL) and solid tumors, and were able to connect with the #CancerResearch community. Leveraging #ArtificialIntelligence, #MachineLearning, and #genomics, Lantern Pharma Inc. (Nasdaq: LTRN) is working towards transforming the cost, pace, and timeline of oncology drug discovery and development. Check out the poster on our website! https://lnkd.in/e_j4azc9 #oncology #drugdiscovery #drugdevelopment #oncologyresearch #AI #Genomics #ML #Datascience #24AACR #AACR2024 American Association for Cancer Research

The oncology space is dynamic, with many novel interventions undergoing clinical trials. Today, we dive into the EXAM study, a Phase III clinical trial conducted by Exelixis to assess the progression-free survival (PFS) with cabozantinib vs. placebo in patients with unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC). #Oncology #MetastaticMedullaryThyroidCancer #CancerTreatment #EXAMStudy #ClinitalTrials #Cabozantinib